Cerus Corporation (CERS) is set to release its quarterly earnings report on Wednesday, October 30th, 2024. Analysts are projecting an EPS of -$0.03, and investors will be keenly watching for guidance on the next quarter. This article provides an in-depth look at Cerus’s past performance, analyst expectations, and a comparison to its peers, highlighting key financial metrics.
Cue Biopharma Inc. (CUE) exceeded earnings expectations in the second quarter of 2024, reporting a smaller-than-expected loss and exceeding revenue estimates. The company’s strong performance and positive earnings outlook have earned it a Zacks Rank #2 (Buy), indicating potential for outperformance in the near future. This comes despite the stock’s decline earlier this year. Meanwhile, the Medical – Biomedical and Genetics industry remains strong, suggesting continued positive momentum for Cue Biopharma.
